Are Rajkamal Synthetics Ltd latest results good or bad?

1 hour ago
share
Share Via
Rajkamal Synthetics Ltd's latest results show strong revenue growth of 223.30% year-on-year, but net profit has declined 36.54% year-on-year, raising concerns about profitability due to significant margin compression. Recent declines in both sales and profits indicate operational challenges that may impact future performance.
Rajkamal Synthetics Ltd's latest financial results reflect a complex operational landscape. In Q2 FY26, the company reported net profit of ₹0.99 crores, which represents a quarter-on-quarter increase of 20.73%. However, this figure is down 36.54% year-on-year from ₹1.56 crores. Revenue for the same quarter reached ₹17.62 crores, showing a robust sequential growth of 22.87% and a substantial year-on-year increase of 223.30% from ₹2.38 crores. This dramatic revenue growth indicates successful scaling of operations.
Despite the impressive revenue figures, the company's profitability margins have faced significant compression. The operating margin plummeted to 6.47% from 28.99% in the same quarter last year, while the PAT margin also fell sharply from 28.62% to 5.62%. This decline raises concerns about the sustainability and quality of the revenue growth, suggesting potential challenges in maintaining profitability amid rising costs or unfavorable product mix. In the subsequent quarter ended December 2025, Rajkamal Synthetics experienced a decline in both net sales and net profit, with net sales dropping by 24.43% and net profit decreasing by 28.57% compared to the previous quarter. The operating profit margin remained relatively stable at 6.77%, indicating some resilience in operational efficiency despite the overall downturn in sales and profit. Overall, while Rajkamal Synthetics has demonstrated strong revenue growth, the significant margin compression and recent declines in both sales and profits highlight operational challenges that may affect its future performance. Additionally, the company saw an adjustment in its evaluation, reflecting the ongoing complexities in its financial health.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News